Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent - five-year results of the TARGET All Comers randomised clinical trial.
Lansky AJ, Xu B, Baumbach A, Kelbæk H, van Royen N, Zheng M, Knaapen P, Slagboom T, Johnson TW, Vlachojannis GJ, Arkenbout KE, Holmvang L, Janssens L, Brugaletta S, Naber CK, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina CM, Buszman PE, Thiele H, Schächinger V, Wijns W. Lansky AJ, et al. Among authors: arkenbout ke. EuroIntervention. 2023 Dec 4;19(10):e844-e855. doi: 10.4244/EIJ-D-23-00409. EuroIntervention. 2023. PMID: 37860860 Free article. Clinical Trial.
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial.
Lansky A, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Baumbach A; TARGET All Comers Investigators. Lansky A, et al. Among authors: arkenbout ke. Lancet. 2018 Sep 29;392(10153):1117-1126. doi: 10.1016/S0140-6736(18)31649-0. Epub 2018 Sep 3. Lancet. 2018. PMID: 30190206 Clinical Trial.
2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent.
Xu B, Saito Y, Baumbach A, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Lansky A, Wijns W; TARGET AC Investigators. Xu B, et al. Among authors: arkenbout ke. JACC Cardiovasc Interv. 2019 Sep 9;12(17):1679-1687. doi: 10.1016/j.jcin.2019.05.001. Epub 2019 May 22. JACC Cardiovasc Interv. 2019. PMID: 31129092 Free article. Clinical Trial.
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial.
Kerkmeijer LSM, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout KE, Kraak RP, Weevers A, Piek JJ, de Winter RJ, Tijssen JGP, Henriques JPS, Wykrzykowska JJ; Collaborators. Kerkmeijer LSM, et al. Among authors: arkenbout ke. EuroIntervention. 2019 Sep 20;15(7):603-606. doi: 10.4244/EIJ-D-19-00325. EuroIntervention. 2019. PMID: 31147304 Free article. No abstract available.
Identification of anatomic risk factors for acute coronary events by optical coherence tomography in patients with myocardial infarction and residual nonflow limiting lesions: rationale and design of the PECTUS-obs study.
Mol JQ, Belkacemi A, Volleberg RH, Meuwissen M, Protopopov AV, Laanmets P, Krestyaninov OV, Dennert R, Oemrawsingh RM, van Kuijk JP, Arkenbout K, van der Heijden DJ, Rasoul S, Lipsic E, Teerenstra S, Camaro C, Damman P, van Leeuwen MA, van Geuns RJ, van Royen N. Mol JQ, et al. BMJ Open. 2021 Jul 7;11(7):e048994. doi: 10.1136/bmjopen-2021-048994. BMJ Open. 2021. PMID: 34233996 Free PMC article.
Fractional Flow Reserve-Negative High-Risk Plaques and Clinical Outcomes After Myocardial Infarction.
Mol JQ, Volleberg RHJA, Belkacemi A, Hermanides RS, Meuwissen M, Protopopov AV, Laanmets P, Krestyaninov OV, Dennert R, Oemrawsingh RM, van Kuijk JP, Arkenbout K, van der Heijden DJ, Rasoul S, Lipsic E, Rodwell L, Camaro C, Damman P, Roleder T, Kedhi E, van Leeuwen MAH, van Geuns RM, van Royen N. Mol JQ, et al. JAMA Cardiol. 2023 Nov 1;8(11):1013-1021. doi: 10.1001/jamacardio.2023.2910. JAMA Cardiol. 2023. PMID: 37703036
Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry.
Kalkman DN, Woudstra P, Menown IBA, den Heijer P, Van't Hof AW, Erglis A, Suryapranata H, Arkenbout KE, Iñiguez A, Muller P, Tijssen JG, Beijk MAM, de Winter RJ. Kalkman DN, et al. Among authors: arkenbout ke. Open Heart. 2017 Jul 11;4(2):e000634. doi: 10.1136/openhrt-2017-000634. eCollection 2017. Open Heart. 2017. PMID: 28761685 Free PMC article.
Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry.
Kalkman DN, Kerkmeijer LS, Woudstra P, Menown IBA, Suryapranata H, den Heijer P, Iñiguez A, van 't Hof AWJ, Erglis A, Arkenbout KE, Muller P, Koch KT, Tijssen JG, Beijk MAM, de Winter RJ. Kalkman DN, et al. Among authors: arkenbout ke. Catheter Cardiovasc Interv. 2019 Sep 1;94(3):342-347. doi: 10.1002/ccd.28047. Epub 2018 Dec 18. Catheter Cardiovasc Interv. 2019. PMID: 30565371
Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent.
Kerkmeijer LSM, Chandrasekhar J, Kalkman DN, Woudstra P, Menown IBA, Suryapranata H, den Heijer P, Iñiguez A, van 't Hof AWJ, Erglis A, Arkenbout KE, Muller P, Koch KT, Tijssen JG, Beijk MAM, de Winter RJ. Kerkmeijer LSM, et al. Among authors: arkenbout ke. Catheter Cardiovasc Interv. 2021 Sep;98(3):503-510. doi: 10.1002/ccd.29305. Epub 2020 Oct 8. Catheter Cardiovasc Interv. 2021. PMID: 33029937 Free PMC article.
One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent.
Kalkman DN, Woudstra P, den Heijer P, Menown IB, Erglis A, Suryapranata H, Arkenbout KE, Iñiguez A, van 't Hof AW, Muller P, Tijssen JG, de Winter RJ. Kalkman DN, et al. Among authors: arkenbout ke. Int J Cardiol. 2017 Jan 1;226:60-64. doi: 10.1016/j.ijcard.2016.10.032. Epub 2016 Oct 17. Int J Cardiol. 2017. PMID: 27788391 Free article. Clinical Trial.
14 results